Merus to Present at the Jefferies 2017 Global Healthcare Conference
Jun 01, 2017 11:17 am UTC| Business
UTRECHT, The Netherlands, June 01, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief...
Merus to Present at the Jefferies 2017 Global Healthcare Conference
Jun 01, 2017 11:17 am UTC| Business
UTRECHT, The Netherlands, June 01, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief...
Merus to Present at the Jefferies 2017 Global Healthcare Conference
Jun 01, 2017 11:17 am UTC| Business
UTRECHT, The Netherlands, June 01, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief...
Merus to Present at the Jefferies 2017 Global Healthcare Conference
Jun 01, 2017 11:17 am UTC| Business
UTRECHT, The Netherlands, June 01, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief...
Merus to Present at the Jefferies 2017 Global Healthcare Conference
Jun 01, 2017 11:17 am UTC| Business
UTRECHT, The Netherlands, June 01, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief...
Merus to Present at the Jefferies 2017 Global Healthcare Conference
Jun 01, 2017 11:17 am UTC| Business
UTRECHT, The Netherlands, June 01, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief...
Merus to Present at the Jefferies 2017 Global Healthcare Conference
Jun 01, 2017 11:17 am UTC| Business
UTRECHT, The Netherlands, June 01, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief...
Australia’s Corporate Regulator Urges Pension Funds to Boost Technology Investment as Industry Grows